Inside Arcellx’s Revolutionary Approach to Cell Therapy

Description

“The first decision I had to make when I joined was whether to continue this anito-cel program that now looks to be potentially best-in-class in myeloma,” Rami Elghandour, CEO of Arcellx, tells Bloomberg Intelligence analyst Sam Fazeli. The company embodies the dream of biotech investors — raising a small amount of capital while on the cusp of getting a drug to market with a credible partner. Arcellx and Gilead aim to take on the leader in multiple myeloma, Johnson & Johnson, targeting its engineered T-cell therapy (CAR-T) Carvykti with their own unique CAR-T, anito-cel. The discussion covers topics from the company’s inception to Elghandour’s journey through health care and how it has a real chance of launching a product after raising just $240 million. Oh, and Spider Man makes a cameo appearance, too.